Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome

Journal of Hepatology

Volumn 45, Issue 6, 2006, Pages 881-882

  Haukeland, John Willy ^a   Aukrust, Pål ^b,c  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b Research Institute for Internal Medicine   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LETTER; LIVER HISTOLOGY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 33750430289     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.09.006     Document Type: Letter

References (6)

1. Haukeland J.W., Damas J.K., Konopski Z., Loberg E.M., Haaland T., Goverud I., et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44 (2006) 1167-1174
2. Ford E.S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168 (2003) 351-358
3. Koh K.K., Han S.H., and Quon M.J. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 46 (2005) 1978-1985
4. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
5. Malik S., Wong N.D., Franklin S., Pio J., Fairchild C., and Chen R. Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28 (2005) 690-693
6. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695